Canada and the United States, whose governments have cooperated in the development of the vaccine, have already authorized its use.
The European Medicines Agency (EMA) this Friday formally recommended the use of the Imvanex smallpox vaccine to prevent monkeypox.
Several EU countries, including Spain, are already using this drug against monkeypox, but not without first consulting the EMA, which already considers it a “potential” vaccine against the disease, noting that That the smallpox virus has similarities with the community. Sources explained to EFE.
In fact, Canada and the United States, whose governments have collaborated in the development of the vaccine, have already authorized its use to prevent cases of monkeypox.
The European Commission had already authorized its use against smallpox in 2013, and the EMA Committee for Medicinal Products for Human Use (CHMP) today formally approved it as a treatment for monkeypox after concluding an analysis that began on 28 June. recommended to expand.
Thus, the CHMP based its recommendation on several animal studies that “showed protection against monkeypox virus in non-human primates vaccinated with Imvanex,” the EMA explained in a statement.
“The CHMP considers that the efficacy of Imvanex in preventing monkeypox in humans is predictable,” the agency continued, which said the agency, which assured that the drug has “mild” or “moderate” side effects, although any In the case “the benefit outweighs the drug risk.”
The EMA will now continue to collect data to confirm the effectiveness of the monkeypox vaccine.
